Navigation Links
Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials
Date:12/15/2009

PHILADELPHIA and LONDON, Dec. 15 /PRNewswire/ -- Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

Thomson Pharma will offer drug related clinical trial intelligence from registries, publications, press releases, conferences, and other sources across all therapeutic areas. It includes some of the most advanced searching capabilities on the market, enabling identification of trials based on over twenty criteria that are individually indexed by experts. This includes not only trial criteria such as drug, phase and recruitment status, but also scientific criteria such as mechanism of action, target and biomarker.

"We are proud to be the first to integrate drug pipeline content with robust clinical trial content in a single competitive intelligence solution," said Wendy Hamilton, vice president of product strategy at Thomson Reuters. "This not only addresses our customers' needs for increased efficiency and new competitive insights, but also ensures that Thomson Pharma will remain the most comprehensive single solution for pharmaceutical competitive intelligence on the market."

Thomson Pharma covers the entire drug discovery and development pipeline -- the drugs, compounds, targets, companies, clinical trials, patents, journals, conferences, academic articles and more. For more information, please visit: go.thomsonreuters.com/thomsonpharma.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange ( TRI). For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Thomson Reuters Predicts Nobel Laureates
4. Thomson Joins Brooks Kushman; Strengthens Los Angeles Presence
5. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
6. Thomson Reuters Joins the InChI Trust
7. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
8. Thomson Reuters Partners With Sagient Research
9. Brazils Scientific Research On The Rise, Thomson Reuters Study Finds
10. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
11. Thomson Reuters Examines Highly Cited Research in Bioterrorism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):